

Special Issue

Brain Injury and Neurodegeneration: Molecular, Functional, and Translational Approach 2.0

Message from the Guest Editors

With the advance of neuroscience research, we have come across different kinds of brain pathologies such as traumatic brain injury (TBI), hypoxic/hypobaric insults, hemorrhages, stroke, and neurological disorders such as Parkinson's and Alzheimer's diseases. Any insult to brain (mild or acute) is multifactorial and initiates a cascade of inflammation, necrotic, and apoptotic pathways. It has long been known that insult or injury to brain may lead to neurological disorders as time elapses, and genetic or environmental factors play important roles in the progression of disease. A large body of evidence has shown that oxidative stress, mitochondrial dysfunctions, protein aggregation and phosphorylation, excessive iron accumulation in the brain, and neuro-inflammation play a pivotal role in neurodegeneration and brain injuries. The absence of a specific cure to limit injury progression after insult has spurred the scientific community to study the mechanism behind the degenerative cascade and to explore different therapeutic strategies. This Special Issue will provide a multidisciplinary platform for discussing the pathology and intervention of brain disorders.

Guest Editors

Dr. Kumar Vaibhav

Dr. Pankaj Ahluwalia

Dr. Pankaj Gaur

Dr. Meenakshi Ahluwalia

Deadline for manuscript submissions

closed (30 June 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/102636

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).